| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.3 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.18 | 0.3 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |